Search research articles
Contact Us
Filters
Showing results (31-40 of 71) with videos related to
Page
of 8
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2011
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study
Christophe Tournigand, Andres Cervantes, Arie Figer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2011
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors
Luis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, et al.
The Oncologist
|
June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
Christopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2010
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study
Josep Tabernero, Andres Cervantes, Fernando Rivera, et al.
Molecular Cancer Therapeutics
|
August 21, 2010
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics
Teresa Macarulla, Andres Cervantes, Elena Elez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 4, 2012
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors
Andres Cervantes, Elena Elez, Desamparados Roda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2019
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastislav Bahleda, Antoine Italiano, Cinta Hierro, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 22, 2019
The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper
Vincenzo Valentini, Corrie Marijnen, Geerard Beets, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 23, 2009
Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma
Fernando Rivera, Maica Galán, Josep Tabernero, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 71) with videos related to
Sort By:
Page
of 8
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2011
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study
Christophe Tournigand, Andres Cervantes, Arie Figer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2011
Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors
Luis G Paz-Ares, Carlos Gomez-Roca, Jean-Pierre Delord, et al.
The Oncologist
|
June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS
Christopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2010
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study
Josep Tabernero, Andres Cervantes, Fernando Rivera, et al.
Molecular Cancer Therapeutics
|
August 21, 2010
Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics
Teresa Macarulla, Andres Cervantes, Elena Elez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 4, 2012
Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors
Andres Cervantes, Elena Elez, Desamparados Roda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2019
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastislav Bahleda, Antoine Italiano, Cinta Hierro, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
August 22, 2019
The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper
Vincenzo Valentini, Corrie Marijnen, Geerard Beets, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 23, 2009
Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma
Fernando Rivera, Maica Galán, Josep Tabernero, et al.
Page
of 8